Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

類似資料

• Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
  著者:: Rocio Garcia-Carbonero, 等
  出版事項: (2017-09-01)
• Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
  著者:: Illingworth, Sam, 等
  出版事項: (2017)
• A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
  著者:: Machiels, Jean-Pascal, 等
  出版事項: (2019)
• "Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours
  著者:: Champion, Brian R, 等
  出版事項: (2014)
• Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators
  著者:: Dyer, Arthur, 等
  出版事項: (2016)